Welcome to our dedicated page for Sanuwave Health news (Ticker: SNWV), a resource for investors and traders seeking the latest updates and insights on Sanuwave Health stock.
Sanuwave Health, Inc. (SNWV) pioneers noninvasive regenerative solutions through its proprietary PACE™ technology, advancing wound care and tissue repair innovations. This dedicated news hub provides investors and medical professionals with essential updates on the company's progress in developing FDA-cleared medical devices.
Access authoritative information about SNWV's technological advancements, including clinical trial outcomes, regulatory milestones, and strategic partnerships. Our curated collection features:
• FDA clearance announcements for new medical devices
• Clinical study results demonstrating treatment efficacy
• Financial performance updates and corporate developments
• Technology licensing agreements and partnership news
Bookmark this page for reliable updates on Sanuwave Health's progress in revolutionizing noninvasive therapies for wound management, orthopedic conditions, and aesthetic procedures. Verify all investment decisions against official SEC filings and consult medical professionals for clinical guidance.
SANUWAVE Health (SNWV) reported a 75% increase in estimated revenue for June year-over-year, attributed to heightened recurring revenue and successful conversions from evaluations. The sales funnel rose by 9% to $23 million, and system trials grew by 5%, totaling 109 trials. The company is closely monitoring these figures for the second quarter and expects some volatility ahead. This positive trend in sales metrics underlines SANUWAVE's commitment to enhancing its wound care portfolio.
SANUWAVE Health (OTC: SNWV) announced a strong performance for May 2022, reporting an estimated revenue increase of 96% year-over-year. The sales funnel also saw a 5% increase, totaling $21.1 million, while system trials rose by 2%, reaching 103 active trials. These trends suggest significant growth potential for the second quarter, although the company anticipates some volatility in these figures going forward. SANUWAVE specializes in innovative wound care and regenerative medicine, focusing on non-invasive medical systems.
SANUWAVE Health reported a significant 100% revenue increase year-over-year for Q1 2022, totaling $3.2 million, up from $2.1 million in 2021. The first quarter's sales were driven by their ENERGY FIRST device line, as the prior year's biologics sales are no longer included. Additionally, April saw a 9% increase in the sales funnel, reaching $19.9 million, while system trials rose 5% to 101. Despite potential volatility, these metrics provide visibility into future revenue growth as the company navigates opportunities in the wound care market.
SANUWAVE Health (SNWV) announced the issuance of several new patents in 2022, enhancing its innovative technology portfolio for advanced wound care and industrial applications. The newly issued patents include innovations in shockwave and ultrasound technologies, with a total of 160 patents now active. Notable patents involve methods for oil separation, tissue disinfection, and underwater cleaning using shockwaves. The company aims to leverage this intellectual property to enhance its competitive edge and explore partnership opportunities, further solidifying its position in both medical and non-medical sectors.
SANUWAVE Health, Inc. (SNWV) announced the addition of three new members to its board of directors, effective Q2 2022. The new members, Ian Miller, Jeffrey Blizard, and Jim Tyler, bring extensive experience in sales and operations within the healthcare industry. CEO Kevin Richardson expressed optimism about the company's growth potential for 2022. The announcement also noted gratitude for departing board member John Nemelka, who has significantly contributed to the company for over 17 years. SANUWAVE focuses on innovative wound care products and regenerative medicine technologies.
SANUWAVE Health (SNWV) reports a 13.1% increase in their sales funnel for March 2022, totaling $18.1 million. System trials also rose 12.9%, indicating strong revenue potential for Q2. The company is expanding into new vertical markets, specifically Sports Medicine and Aesthetics, with initial orders exceeding $1 million set for delivery in Q2 and Q3 2022. Key products include Profile and UltraMIST. SANUWAVE aims to share monthly updates to keep shareholders informed of progress and potential volatility in sales figures.
SANUWAVE Health (SNWV) invites investors to attend its presentation at the Emerging Growth Conference on March 2, 2022, at 11:00 AM ET. This online event allows interaction with CEO Kevin Richardson and CRO Jack Schlechtweg, who will discuss the company's advancements in wound care products and respond to attendee questions. The presentation is set for 30 minutes, and those unable to attend can access an archived version afterward. SANUWAVE is dedicated to innovative non-invasive medical solutions for tissue repair and regeneration.
SANUWAVE Health (SNWV) is set to hold a conference call on March 2, 2022, at 9:00 am ET, to discuss recent business developments, updates on SEC filings, and strategic initiatives. Investors can join by dialing 1-877-407-0784 (toll-free) or 1-201-689-8560 (international). A replay will be available until March 9, 2022, using the passcode 13727564. SANUWAVE specializes in non-invasive wound care technologies aimed at enhancing the body's healing processes.
SANUWAVE Health, Inc. (SNWV) will host a conference call on January 19, 2022, at 9:00 am ET to discuss its recent business activity and provide updates on SEC filings and strategic initiatives. Live call access is available via toll-free number 1-877-407-0784 or international number 1-201-689-8560. A replay can be accessed until February 2, 2022, using toll-free number 1-844-512-2921. SANUWAVE focuses on advanced wound care solutions and regenerative medicine technologies to enhance healing processes.
SANUWAVE Health (SNWV) will host a conference call on October 22, 2021, at 9:00 am ET to review recent business developments, SEC filing updates, and strategic initiatives. Investors can access the call via toll-free numbers: 1-877-407-0784 (U.S.) and 1-201-689-8560 (international). A replay will be available until November 5, 2021, with access numbers: 1-844-512-2921 (U.S.) and 1-412-317-6671 (international), using the passcode 13724589. SANUWAVE focuses on non-invasive medical systems for skin and tissue regeneration, employing patented energy transfer technologies in various health conditions.
